Cancer Advisor | One Day MD

OneDayMD Cancer Resource Library · Network Index · Published September 17, 2026 · Last reviewed and updated October 2026 (v2.1) Cancer information is no longer confined to a single textbook, treatment guideline, or hospital website — and cancer guides should not be limited to oncologists. Modern oncology now spans pathology, staging, molecular biomarkers, precision medicine, prevention, surgery, radiation, chemotherapy, targeted therapy, immunotherapy, cellular therapy, cancer metabolism, treatment resistance, supportive care, and clinical research. This OneDayMD guide brings those subjects together in one navigable resource. Rather than hundreds of disconnected articles, it offers a pathway through the evidence and links directly to deeper OneDayMD, SmartCancer, and Cancer Advisor resources. Quick Answer This page is a map, not a single treatment guide — it connects the OneDayMD network's cancer content by the question you're actually asking. Newly diagnosed and w...

Abstract Background: Repurposed antiparasitic agents—ivermectin (IVM), fenbendazole (FBZ), and mebendazole (MBZ)—have generated public interest as potential adjunctive therapies in advanced malignancies, including stage IV prostate cancer. This narrative review analyzes 37 publicly reported anecdotal cases compiled in a 2025 Substack article (updated 2026) primarily sourced from Dr. William Makis’ X posts. Methods: Cases were extracted from the source article, which organizes 22 core cases into drug-focused tables and lists 15 additional testimonials. Data abstraction focused on patient demographics, disease characteristics, treatment regimens, prior therapies, adjuncts, PSA kinetics, imaging outcomes, and clinical ...